SG Americas Securities
AMLX icon

SG Americas Securities’s Amylyx Pharmaceuticals AMLX Stock Holding History

SG Americas Securities’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$994K Buy
+55,321
New +$856K ﹤0.01% 1884
2026
Q1 		– Sell
-20,846
Closed -$252K – 3196
2025
Q4 		$252K Buy
20,846
+9,027
+76% +$123K ﹤0.01% 2836
2025
Q3 		$161K Buy
+11,819
New +$111K ﹤0.01% 2859
2025
Q2 		– Sell
-25,210
Closed -$89K – 2909
2025
Q1 		$89K Buy
25,210
+9,252
+58% +$32.9K ﹤0.01% 3086
2024
Q4 		$60K Sell
15,958
-41,428
-72% -$195K ﹤0.01% 2869
2024
Q3 		$186K Buy
57,386
+1,550
+3% +$3.48K ﹤0.01% 2556
2024
Q2 		$106K Buy
55,836
+29,697
+114% +$57.5K ﹤0.01% 2519
2024
Q1 		$74K Sell
26,139
-39,900
-60% -$522K ﹤0.01% 2638
2023
Q4 		$972K Buy
66,039
+44,784
+211% +$686K 0.01% 1041
2023
Q3 		$389K Buy
21,255
+12,936
+155% +$274K ﹤0.01% 1926
2023
Q2 		$179K Sell
8,319
-869
-9% -$23.5K ﹤0.01% 1840
2023
Q1 		$270K Sell
9,188
-1,301
-12% -$45.2K ﹤0.01% 2197
2022
Q4 		$388K Buy
+10,489
New +$372K ﹤0.01% 1730

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

SG Americas Securities's AMLX Position: Q2 2026 in Review

SG Americas Securities opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 55,321 shares worth $994K. The stake represents ﹤0.01% of the portfolio and ranks #1884 among its holdings. This is a return to the name: SG Americas Securities previously reported a position in AMLX as recently as Q4 2025.

SG Americas Securities first reported a position in AMLX in Q4 2022 and has held it in 13 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • SG Americas Securities held 55,321 shares of Amylyx Pharmaceuticals worth $994K as of Q2 2026.
  • Amylyx Pharmaceuticals was a new SG Americas Securities position in Q2 2026.
  • Amylyx Pharmaceuticals made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1884 holding.
  • SG Americas Securities first reported a position in Amylyx Pharmaceuticals in Q4 2022 and has held it in 13 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.